Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00900562 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
A Phase 2 study, sponsored by PharmaMar.
- Terminated
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT00900562 is a Phase 2 study that was terminated before completion, run by PharmaMar. The registered enrollment target is 19 participants.
The verdict
NCT00900562, a Phase 2 study, was terminated before completion, sponsored by PharmaMar.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study is a phase II clinical and pharmacokinetic trial of PM00104 (Zalypsis®) in patients with advanced and/or metastatic endometrial or cervical cancer previously treated with one line of systemic chemotherapy to evaluate the antitumor activity and to determine the safety profile, the pharmacokinetic profile and the pharmacogenomic profile.
Interventions
- DRUG Zalypsis ( PM00104)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00900562
The ClinicalTrials.gov registry entry for NCT00900562 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PharmaMar, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zalypsis ( PM00104) is the first listed.
NCT00900562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00900562 about?
NCT00900562 is a clinical study titled "Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy". This study is a phase II clinical and pharmacokinetic trial of PM00104 (Zalypsis®) in patients with advanced and/or metastatic endometrial or cervical cancer previously treated with one line of systemic chemotherapy to evaluate the antitumor activity and to determine the safety profile, the pharmaco...
What is the current status of trial NCT00900562?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2009-08. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00900562?
The interventions under investigation include: Zalypsis ( PM00104) (DRUG).
Who is sponsoring clinical trial NCT00900562?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.